Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD

Willemijn J. Van Rijt, M. Rebecca Heiner-Fokkema, Gideon J. du Marchie Sarvaas, Hans R. Waterham, Robert G. T. Blokpoel, Francjan J. van Spronsen, Terry G. J. Derks*

*Corresponding author voor dit werk

    OnderzoeksoutputAcademicpeer review

    23 Citaten (Scopus)

    Samenvatting

    Multiple acyl coenzyme A dehydrogenase deficiency (MADD) is a severe inborn error of metabolism. Experiences with sodium-D,L-3-hydroxybutyrate (3-HB) treatment are limited although positive; however, the general view on outcome of severely affected patients with MADD is relatively pessimistic. Here we present an infant with MADD in whom the previously reported dose of 3-HB did not prevent the acute, severe, metabolic decompensation or progressive cardiomyopathy in the subsequent months. Only after a physiologic dose of 2600 mg/kg of 3-HB per day were ketone bodies detected in blood associated with improvement of the clinical course, N-terminal prohormone of brain natriuretic peptide and echocardiographic parameters. Long-term studies are warranted on 3-HB treatment in patients with MADD.

    Originele taal-2English
    Pagina's (van-tot)e1224-e1228
    Aantal pagina's5
    TijdschriftPediatrics
    Volume134
    Nummer van het tijdschrift4
    DOI's
    StatusPublished - okt.-2014

    Vingerafdruk

    Duik in de onderzoeksthema's van 'Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit